Last update 14 Jun 2025

Anti-CD33 CAR-NK cell therapy ( Sichuan Kelun-Biotech Biopharmaceutical)

Overview

Basic Info

Drug Type
CAR-NK
Synonyms-
Target
CD33
Action
inhibitors
Mechanism
CD33 inhibitors(Myeloid cell surface antigen CD33 inhibitors), Gene transference(Gene transference), Natural killer cell replacements
Therapeutic Areas
NeoplasmsHemic and Lymphatic Diseases
Active Indication-
Inactive Indication
Refractory acute myeloid leukemia
Originator Organization
Sichuan Kelun Pharmaceutical Co., Ltd.Sichuan Kelun Pharmaceutical Co., Ltd.
Active Organization-
Inactive Organization
Sichuan Kelun Botai Biomedicine Co., Ltd.Sichuan Kelun Botai Biomedicine Co., Ltd.
License Organization-
Drug Highest PhasePendingPhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with Anti-CD33 CAR-NK cell therapy ( Sichuan Kelun-Biotech Biopharmaceutical)
NCT05008575
/ Unknown statusPhase 1IIT
Phase I Study to Evaluate the Safety and Effectiveness of Anti-CD33 CAR NK Cell Therapy in Relapsed/Refractory Acute Myeloid Leukemia
100 Clinical Results associated with Anti-CD33 CAR-NK cell therapy ( Sichuan Kelun-Biotech Biopharmaceutical)
Login to view more data
100 Translational Medicine associated with Anti-CD33 CAR-NK cell therapy ( Sichuan Kelun-Biotech Biopharmaceutical)
Login to view more data
100 Patents (Medical) associated with Anti-CD33 CAR-NK cell therapy ( Sichuan Kelun-Biotech Biopharmaceutical)
Login to view more data
100 Deals associated with Anti-CD33 CAR-NK cell therapy ( Sichuan Kelun-Biotech Biopharmaceutical)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Refractory acute myeloid leukemiaPhase 1
China
Sichuan Kelun Botai Biomedicine Co., Ltd.Sichuan Kelun Botai Biomedicine Co., Ltd.
23 Dec 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT05008575 (ASH 12022 | ASH 22022)
ManualManual
Phase 1
Relapsing acute myeloid leukemia | Refractory acute myeloid leukemia
10
awvidzkccv(dddojclidz) = qrzroyqoez yrsjbehajj (yakjnydsgd )
View more
Positive
15 Nov 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free